Trial Profile
Incidence of symptomatic lymphocele and lymphadenectomy in patients with ovarian cancer who treated with TachoSil (fibrinogen/thrombin): A rerospective pilot study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2017
Price :
$35
*
At a glance
- Drugs Fibrinogen/thrombin (Primary)
- Indications Surgical blood loss
- Focus Adverse reactions
- 16 May 2017 New trial record